| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.74 [0.54, 1.01] | | < 1 | | 64% | 2 studies (2/-) | 97.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.63 [0.52, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.53 [0.44, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.57 [0.43, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.65 [0.51, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 3.40 [2.02, 5.72] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) (extension) | 3.54 [2.46, 5.10] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.49 [0.20, 1.23] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.28 [0.21, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.15 [0.10, 0.21] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.11 [0.07, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.51 [0.13, 1.97] | | < 1 | | 93% | 2 studies (2/-) | 83.6 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.37 [0.11, 1.31] | | < 1 | | 96% | 2 studies (2/-) | 93.7 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.42 [0.04, 4.84] | | < 1 | | 0% | 2 studies (2/-) | 75.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.29 [0.05, 1.70] | | < 1 | | 97% | 2 studies (2/-) | 91.4 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.21 [0.04, 1.23] | | < 1 | | 95% | 2 studies (2/-) | 95.8 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.34 [0.03, 3.37] | | < 1 | | 0% | 2 studies (2/-) | 82.0 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.79 [0.20, 3.18] | | < 1 | | 0% | 2 studies (2/-) | 62.9 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.79 [0.11, 5.64] | | < 1 | | 0% | 2 studies (2/-) | 59.1 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.34 [0.07, 1.72] | | < 1 | | 0% | 2 studies (2/-) | 90.3 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 0.12 [0.03, 0.39] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 3.99 [0.18, 88.92] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.27 [0.09, 0.84] | | < 1 | | 75% | 2 studies (2/-) | 98.8 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.72 [0.22, 2.31] | | < 1 | | 0% | 2 studies (2/-) | 71.0 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.10 [0.05, 0.20] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.20 [0.03, 1.19] | | < 1 | | 0% | 2 studies (2/-) | 96.1 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.15 [0.07, 0.32] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.00 [0.10, 9.63] | | < 1 | | 0% | 2 studies (2/-) | 50.0 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.18 [0.05, 0.63] | | < 1 | | 0% | 2 studies (2/-) | 99.6 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.60 [0.08, 4.68] | | < 1 | | 0% | 2 studies (2/-) | 68.5 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.37 [0.03, 5.15] | | < 1 | | 81% | 2 studies (2/-) | 76.9 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.35 [0.09, 1.47] | | < 1 | | 67% | 2 studies (2/-) | 92.2 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.17 [0.53, 2.56] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.36 [0.01, 12.15] | | < 1 | | 72% | 2 studies (2/-) | 71.3 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.64 [0.06, 6.33] | | < 1 | | 0% | 2 studies (2/-) | 64.7 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.33 [0.03, 3.13] | | < 1 | | 21% | 2 studies (2/-) | 83.2 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.34 [0.03, 3.37] | | < 1 | | 0% | 2 studies (2/-) | 82.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.31 [0.12, 0.80] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.12 [0.01, 2.36] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.18 [0.07, 0.46] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
